Avidity Biosciences ( (RNA) ) has provided an update.
On March 17, 2025, Avidity Biosciences announced the topline data from its Phase 1/2 EXPLORE44 trial for delpacibart zotadirsen (del-zota) in patients with Duchenne muscular dystrophy amenable to exon 44 skipping. The trial results showed consistent delivery of PMOs to skeletal muscle, increased exon 44 skipping, enhanced dystrophin production, and reduced creatine kinase levels, demonstrating favorable safety and tolerability. The company plans to submit a Biologics License Application by the end of 2025, aiming for accelerated approval in the U.S.
More about Avidity Biosciences
Avidity Biosciences operates in the biotechnology industry, focusing on the development of RNA therapeutics. The company is known for its work on rare neuromuscular disorders, including Duchenne muscular dystrophy (DMD), and is advancing its product candidates through clinical trials with a focus on accelerated approval pathways.
YTD Price Performance: -0.22%
Average Trading Volume: 1,355,202
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.74B
For a thorough assessment of RNA stock, go to TipRanks’ Stock Analysis page.